Alice Blue - 20 years of trust
    • ANT APP
    • ANT WEB
    • 1LyAlgos
    • 1lyOptions
    • TradingView
    • MTF
    • Insurance
    • IPO
    • Stocks
    • Mutual Funds
  • Partner with us
  • Trade School
  • Pricing

    • Pricing

    About Us

    • About Us

    Calculator

    • Calculators
    • Brokerage Calculator
    • MTF Calculator

    Resources

    • Blog
    • Webinars
    • Videos (YouTube)

    Updates

    • News
    • Trading Holidays
    • Cares
    • Media Coverage
    • Disclosures

    Support

    • Support
    • Refer & Earn
    CommunityCareers
Login

    Start Investing in Stocks₹0 Account Opening

    +91
    Top Gainers Today52 Weeks High StocksHistorical Returns StocksShare Market TodayTop Losers TodayStocks Market NewsPC JewellerVodafone IdeaYes BankJyoti StructuresPunjab Natl.BankMoneyviewI R F CCanara BankKalyan JewellersSuzlon EnergyAshoka BuildconHDFC BankTata Gold ETFGACM TechGTL Infra.Bank of BarodaRail VikasMotisons JewelReliance Power
    NIFTY 50NIFTY Midcap 100NIFTY 100NIFTY RealtySENSEXNIFTY AutoNIFTY PSU BankNIFTY FMCGNIFTY BANKNIFTY MIDCAP 150BSE EnergyNIFTY PharmaBSE 100 LargeCap TMCNIFTY NEXT 50NIFTY MetalBSE 500 QUALITY 50
    Options Nifty 50Options BANK NIFTYOptions MIDCPNIFTYOptions FINNIFTYFutures Highest OIFutures OI GainersFutures OI LosersFutures Top Traded
    Debt Mutual FundsBest Debt Mutual fundsBest Equity Mutual fundsBest Hybrid Mutual fundsBest MidCap Mutual fundsBest Multicap Mutual fundsBest Large Cap Mutual fundsBest Small Cap Mutual fundsBest ELSS Mutual fundsBest Contra Mutual fundsBest Value Mutual fundsBest Arbitrage Mutual fundsBest Dividend Yield Mutual fundBest Aggressive Mutual fundsBest Conservative Mutual funds
    SIP CalculatorBrokerage CalculatorHome Loan EMI CalculatorLumpsum CalculatorMargin CalculatorFD CalculatorSWP CalculatorMF CalculatorEMI CalculatorStep-Up SIP CalculatorPPF Calculator
    What Is IPO?Open IPOsUpcoming IPOsHow to Apply for an IPOWhat is Grey Market Premium?
    Shares
    Top Gainers Today52 Weeks High StocksHistorical Returns StocksShare Market TodayTop Losers TodayStocks Market NewsPC JewellerVodafone IdeaYes BankJyoti StructuresPunjab Natl.BankMoneyviewI R F CCanara BankKalyan JewellersSuzlon EnergyAshoka BuildconHDFC BankTata Gold ETFGACM TechGTL Infra.Bank of BarodaRail VikasMotisons JewelReliance Power
    Indices
    NIFTY 50NIFTY Midcap 100NIFTY 100NIFTY RealtySENSEXNIFTY AutoNIFTY PSU BankNIFTY FMCGNIFTY BANKNIFTY MIDCAP 150BSE EnergyNIFTY PharmaBSE 100 LargeCap TMCNIFTY NEXT 50NIFTY MetalBSE 500 QUALITY 50
    F&O
    Options Nifty 50Options BANK NIFTYOptions MIDCPNIFTYOptions FINNIFTYFutures Highest OIFutures OI GainersFutures OI LosersFutures Top Traded
    Mutual Funds
    Debt Mutual FundsBest Debt Mutual fundsBest Equity Mutual fundsBest Hybrid Mutual fundsBest MidCap Mutual fundsBest Multicap Mutual fundsBest Large Cap Mutual fundsBest Small Cap Mutual fundsBest ELSS Mutual fundsBest Contra Mutual fundsBest Value Mutual fundsBest Arbitrage Mutual fundsBest Dividend Yield Mutual fundBest Aggressive Mutual fundsBest Conservative Mutual funds
    Calculators
    SIP CalculatorBrokerage CalculatorHome Loan EMI CalculatorLumpsum CalculatorMargin CalculatorFD CalculatorSWP CalculatorMF CalculatorEMI CalculatorStep-Up SIP CalculatorPPF Calculator
    IPO
    What Is IPO?Open IPOsUpcoming IPOsHow to Apply for an IPOWhat is Grey Market Premium?

    Company
    • About Us
    • Work with Us
    • Terms and Conditions
    • EKYC Guidelines
    • Contact Us
    • Cares
    Apps and Products
    • ANT APP
    • ANT WEB
    • 1LYOptions
    • Trade School
    • TradingView
    • 1LyAlgos
    Calculators
    • Calculators
    • SIP Calculator
    • Mutual Funds Return Calculator
    • Brokerage Calculator
    • RMS Live Updates
    • Term Coverage Calculator
    Important Links
    • Pricing
    • KYC Tracker
    • Market News
    • Global Indices
    • Gold Rate
    • Silver Rate
    • Trading Holidays

    Alice Blue
    3rd Floor, M.R.B.Arcade, No. 153/2,
    Bagalur Main Rd, Dwarka Nagar,
    Yelahanka, Bengaluru, Karnataka
    560063
    FacebookLinkedInX (Twitter)YouTubeInstagramWhatsapp

    ISO 27001:2022 Alice Blue is Certified Information Security Management System (ISMS)

    ISO 22301:2019 Alice Blue is Certified Business Continuity Management System (BCMS)

    DownloadsCircularsBank DetailsLearn
    Trade on TradingViewGet it on Google PlayDownload on the App Store

    Attention Investors!
    Prevent unauthorized transactions in your account update your mobile number/ email Id with your Stock Broker. Receive information of your transactions directly from Exchange on your mobile / email id at the end of the day.Prevent unauthorized transactions in your account update your mobile number/ email Id with your Stock Broker. Receive information of your transactions directly from Exchange on your mobile / email id at the end of the day.

    Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from the depository on your email id and/or mobile number to create a pledge. Pay 20% upfront margin of the transaction early to trade in the cash market segment. Investors may please refer to the Exchange’s Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020, and NSE/INSP/45534 dated August 31, 2020, and other guidelines issued from time to time in this regard. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

    Corporate Office: No. 153/2, 3rd Floor, M.R.B.Arcade, Bagalur Main Road, Dwaraka Nagar, Yelahanka, Bengaluru – 560 063, Karnataka.
    Registered Office: Old No.56/2 ,New No.58, LIC Nagar, Vinayagar Kovil Street, Erode -8,Tamil Nadu– 638002.
    Alice Blue Financial Services (P) Ltd : NSE EQ | NSE FO | NSE CDS-90112 SEBI REG : INZ000156038
    Alice Blue Financial Services (P) Ltd : BSE EQ | BSE FO | BSE CD-6670 SEBI REG : INZ000156038
    Alice Blue Financial Services (P) Ltd : CDSL DP ID 12085300 DP SEBI REG : IN-DP-364-2018
    Alice Blue Financial Services (P) Ltd : MCX-56710 SEBI REG : INZ000156038

    COMPLIANCE OFFICER: SARAVANAN R | Mobile No: +91 91872 10670 | Email:[email protected]

    We hereby declare that we are doing PRO trading

    Procedure to file a complaint on SEBI SCORES / SMART ODR : Register on SEBI SCORES 2.0 / SMART ODR. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances

    Click on the provided link to learn about the process for submitting a complaint on the ODR platform for resolving investor grievances. ODR Circular

    Investment in securities markets are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit.

    For queries regarding account opening or activation, email to accountactivation@aliceblueindia.com and for fund updates, email to funds@aliceblueindia.com

    Disclaimer: Attention investors:1) Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors. 2) Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. 3) Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. 4) For demat and trading account closure with AliceBlue, kindly visit https://aliceblueonline.com/support/closure-freezing-reactivation or “ANT APPLICATION” under your profile and click on Settings -> Account Closure section -> Initiate account closure.

    No need to issue cheques by investors while subscribing to an IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in the investor’s account.

    Investors are requested to note that Alice Blue Financial Services Private Limited is permitted to receive money from investor through designated bank accounts only named as Up streaming Client Nodal Bank Account (USCNBA). Alice Blue Financial Services Private Limited is also required to disclose these USCNB accounts to Stock Exchange. Hence, you are requested to use following USCNB accounts only for the purpose of dealings in your trading account with us. The details of these USCNB accounts are also displayed by Stock Exchanges on their website under “Know/ Locate your Stock Broker. Bank Details (Valid UPI FAQ).

    DND PolicyInvestor CharterLegal DocumentationPrivacy policyFeedbackAnnual ReturnsAdvisory for InvestorsE-votingMandatory Member Details

    Performance

    Historical price movement and trading activity

    Trading Data

    Today's High

    587

    Today's Low

    570.5

    Open

    578.5

    Previous Close

    582.35

    Volume

    156433

    Total Traded Value High

    91021220.8

    Technicals

    Price-based indicators and levels

    Indicators

    IndicatorValueSignal
    Relative Strength Index (RSI)+61.91Neutral
    MACD+6.59Bullish

    Support and Resistance Levels

    R3605.90
    R2596.45
    R1589.40
    S1572.90
    S2563.45
    S3556.40

    Moving Averages

    PeriodSMAEMA
    20D Moving Average547.99558.58
    50D Moving Average562.97557.57
    200D Moving Average524.60534.95
    Metropolis Healthcare Ltd

    Metropolis Healthcare Ltd

    NSE: METROPOLIS | BSE: 542650
    ₹575.95-6.40 (-1.10%)
    BuySell

    News

    Metropolis Healthcare climbs as Q1 revenue climbs 16% YoY

    6 Jul 2026

    Metropolis Healthcare jumped 2.97% to Rs 568.40 after the company's revenue grew around 16% YoY in Q1 FY27, driven by patient volumes along with realization benefits due to product mix change.

    The company said the TruHealth Wellness and Specialty segments are the fastest growing segments for the quarter. In B2C business registered healthy volume growth, driven by increased throughput from the expanded center network. B2B volumes also grew, supported by higher wallet share and new customer acquisition, backed by improved service quality and delivery levels. The company said EBITDA margins improved on a YoY basis in line with guidance. On quarter-on-quarter basis, margins remained largely stable. During the Q4 earnings call, promoter Ameer Shah said the company has guided for a sustainable group EBITDA margin of 27%'28% over the next three years. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics. The company's consolidated net profit rose 74.67% to Rs 50.90 crore on 22.99% increase in revenue from operations to Rs 424.68 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live News

    Metropolis Healthcare Ltd leads losers in 'A' group

    22 Jun 2026

    Aadhar Housing Finance Ltd, Black Box Ltd, Tata Capital Ltd and Craftsman Automation Ltd are among the other losers in the BSE's 'A' group today, 22 June 2026.

    Aadhar Housing Finance Ltd, Black Box Ltd, Tata Capital Ltd and Craftsman Automation Ltd are among the other losers in the BSE's 'A' group today, 22 June 2026. Metropolis Healthcare Ltd tumbled 4.49% to Rs 527.4 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 9318 shares were traded on the counter so far as against the average daily volumes of 8023 shares in the past one month. Aadhar Housing Finance Ltd crashed 4.09% to Rs 494.5. The stock was the second biggest loser in 'A' group.On the BSE, 44078 shares were traded on the counter so far as against the average daily volumes of 1.01 lakh shares in the past one month. Black Box Ltd lost 3.95% to Rs 982.4. The stock was the third biggest loser in 'A' group.On the BSE, 27012 shares were traded on the counter so far as against the average daily volumes of 48825 shares in the past one month. Tata Capital Ltd fell 3.86% to Rs 357.2. The stock was the fourth biggest loser in 'A' group.On the BSE, 3.99 lakh shares were traded on the counter so far as against the average daily volumes of 3.8 lakh shares in the past one month. Craftsman Automation Ltd dropped 3.80% to Rs 9478.85. The stock was the fifth biggest loser in 'A' group.On the BSE, 11122 shares were traded on the counter so far as against the average daily volumes of 10180 shares in the past one month. Powered by Capital Market - Live News

    Metropolis Healthcare rallies after Q4 PAT climbs 75% YoY to Rs 51 cr

    14 May 2026

    Metropolis Healthcare jumped 4.23% to Rs 571.30 after the company's consolidated net profit rose 74.67% to Rs 50.90 crore on 22.99% increase in revenue from operations to Rs 424.68 crore in Q4 FY26 over Q4 FY25.

    Profit before exceptional items and tax climbed 93.26% YoY to Rs 69.65 crore in the quarter ended 31st March 2026. The company reported an exceptional loss of Rs 10.69 crore during the quarter. EBITDA stood at Rs 108 crore in Q4 FY26, up 71.3% compared with Rs 63 crore posted in Q4 FY25. EBITDA margin improved to 25.4% in Q4 FY26 as against 18.5% in Q4 FY25. During the quarter, patient volumes grew 11% YoY to 3.5 million, and test volumes increased 14% YoY to 7.6 million, reflecting sustained demand momentum, deeper market penetration and stronger clinician engagement. Revenue per Patient (RPP) improved 11% YoY to Rs 1,210, while Revenue per Test (RPT) increased 8% YoY to Rs 558, supported by favourable mix and higher contribution from specialised testing. The company's B2C revenues grew 20% YoY to Rs 251 crore, driven by higher adoption of preventive and specialized testing, stronger digital engagement and hyperlocal marketing initiatives. B2B revenues increased 28% YoY to Rs 174 crore, aided by strong client retention, hospital outsourcing opportunities, deeper partner relationships and improved service reliability. On a full year basis, the company's consolidated net profit climbed 31.08% to Rs 190.01 crore on 23.64% rise in revenue from operations to Rs 1,645.84 crore in FY26 over FY25. Ameera Shah, promoter and executive chairperson, Metropolis Healthcare, said, 'The diagnostics industry in India is evolving towards more organised and science-led platforms, driven by increasing focus on trust, accuracy and clinical excellence. In Q4FY26, Metropolis delivered robust growth, with revenue increasing 23% YoY, while expanding our network beyond 5,000 centres across India. With healthcare increasingly moving towards preventive and personalised care, we remain committed to building a differentiated diagnostics platform driven by quality, innovation and customer trust.' Surendran Chemmenkotil, managing director, Metropolis Healthcare, said, 'FY26 was an important year from an execution and operating transformation standpoint for Metropolis. Growth during the year was driven by healthy patient volumes, improved mix and stronger realisations, without any price increase in Q4, reflecting the strength of the underlying demand environment. We also made steady progress in productivity, network utilisation, lab optimisation and acquisition integration, supporting operating leverage and meaningful margin expansion. Going forward, we remain focused on driving sustainable growth, improving network throughput and delivering further efficiency-led margin expansion over the medium term.' Meanwhile, the company's board declared 2nd interim dividend of Rs 1 per equity share of face value Rs 2 each for the financial year 2025-26. The record date for the purpose of payment of interim dividend shall be Tuesday, May 19, 2026. The dividend will be paid within 30 days of its declaration. Metropolis Healthcare is India's second-largest pathology laboratory chain, offering diagnostic testing and related services across a nationwide network, with a strong presence in specialised and preventive healthcare diagnostics. Powered by Capital Market - Live News

    Insider Activity

    Sushil Shah Family TrustPromoter
    Acquired
    1167058
    Shares Worth
    ₹0
    Reported On2 Jun 2025
    ModeInter-se Transfer
    Duru Shah Family TrustPromoter Group
    Acquired
    765659
    Shares Worth
    ₹0
    Reported On28 Mar 2025
    ModeInter-se Transfer
    Sushil Shah Family TrustPromoter
    Acquired
    1280267
    Shares Worth
    ₹0
    Reported On4 Apr 2023
    ModeInter-se Transfer
    Duru Shah Family TrustPromoter Group
    Acquired
    1280266
    Shares Worth
    ₹1,54,75,34,330
    Reported On31 Mar 2023
    ModeInter-se Transfer
    DURU SHAH FAMILY TRUSTPromoter Group
    Acquired
    2405840
    Shares Worth
    ₹0
    Reported On30 Mar 2022
    ModeInter-se Transfer
    SUSHIL SHAHPromoter & Director
    Acquired
    427
    Shares Worth
    ₹8,43,205
    Reported On22 Feb 2022
    ModeMarket Purchase

    Showing 1–6 of 9

    Overview

    Healthcare - Diagnostic ServicesNSE / BSE

    Dr. Sushil Kanubhai Shah, one of the Promoters, commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital, having Dr. Kanubhai M. Shah, Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah, Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30, 1981 onwards. In June 1989, upon death of Dr. Kanubhai M. Shah, the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18, 1995, Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20, 1995, the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah, Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners, in the name and style of Metropolis Lab. In January 1998, Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1, 2002, the business of Metropolis Lab was transferred to Dr. V. K. Desai's Hospital as a going concern. In May 2002, Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai's Hospital was changed to Metropolis Health Services in November 2002. Further, in April 2003, Ameera Sushil Shah, Jaswanti Kanubhai Shah, Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services. In July 2003, Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited (MHSIPL). The name of MHSIPL was changed to Metropolis Health Services (India) Limited, pursuant to a Fresh Certificate of Incorporation upon Change of Name to Public Limited Company' on March 1, 2006. In January 2009, MHSIL amalgamated with Pathnet India Private Limited, which was a wholly owned subsidiary of MHSIL. Metropolis Healthcare Limited, formerly known as Pathnet India Private Limited was incorporated in New Delhi on November 10, 2000. The Company is one of India's leading and most trusted pathology laboratory chains, with over four decades of scientific excellence and a strong reputation for delivering accurate, reliable and high-quality diagnostic services. The Company operates a comprehensive diagnostics network across India and select international markets, supported by 210+ clinical laboratories, a 5,000+ service network. Metropolis Healthcare Ltd. came out with an Initial Public Offering (IPO) of 13,685,095 equity shares of Face Value of Rs 2/- each of the company for cash at a price of Rs 880 per equity share aggregating Rs 1204.29 Crores, consisting of an offer for sale of 6,272,335 equity shares by Dr. Sushil Kanubhai Shah (the promoter selling shareholder) aggregating to 551.97 Crores and 7,412,760 equity shares by Ca Lotus Investments (the investor selling shareholder) aggregating 652.32 Crores. The face value of equity shares is Rs 2/-each. The IPO was priced at Rs 880 per equity share. During the year 2018-19, the Wholly Owned Subsidiaries viz., Bacchus Hospitality Services and Real Estate Private Limited; Metropolis Healthcare (Chandigarh) Private Limited, Metropolis Healthcare (Jodhpur) Private Limited, Sanket Metropolis Health Services (India) Private Limited, Final Diagnosis Private Limited and Golwilkar Metropolis Health Services (India) Private Limited amalgamated with the Company (Transferee Company) effective from 08 September 2018. Further, the Transferee Company on 08 September 2018 allotted 26,57,731 fully paid up Equity Shares of Rs 10/- each in the ratio of 957,713 Equity Shares of Rs 10/- each to the shareholders of Bacchus for every 10,00,000 Equity Shares of Rs 10/- each held in Bacchus (Pre-bonus and Sub-division). The wellness initiative TruHealth' was launched across 36cities in FY19; launched Medengage, to nurture upcoming medical talent. A wide range of ~3,487 clinical laboratory tests and 530 profiles were offered by Metropolis as of March 2019. The equity shares of Company were listed on BSE Ltd and the National Stock Exchange of India Limited with effect from April 15, 2019. The Company acquired four frontend labs in Surat in FY 2020. It acquired 51% of stake i.e. 5,100 Equity Shares of Shraddha Diagnostic Centre (I) Private Limited (SDCIPL) from the existing shareholders at a consideration of Rs 9,36,30,000/-. It further acquired a total of 550 equity shares of the Target Company (constituting 5.5 % of its Share Capital) on April 7, 2020 for a consideration of Rs 1 Crores. During the year 2020-21, the Company acquired the balance stake of 49% in Raj Metropolis and with effect from November 5, 2020 and as a result, Raj Metropolis became a wholly-owned subsidiary of the Company. In the financial year 2021-22, Metropolis strengthened its operations by adding 16 labs and 506 network centres, as a part of expansion plan of adding 90 labs and 1,800 network centres by FY 24. It acquired the 100% stake in Dr. Ganesan's Hitech Diagnostics Centre Private Limited along with its subsidiary Centralab Healthcare Services Private Limited and post completion of acquisition, Hitech and Centralab became wholly-owned subsidiary and step down wholly owned subsidiary respectively of Company effective 22 Oct' 2021. Similarly, during the year 2021-22, Company had acquired balance stake of 35% of Metropolis Histoexpert Digital Services Private Limited, Subsidiary of the Company from Koninklijke Philips N.V. Post the acquisition, Metropolis Histoxpert became the wholly-owned Subsidiary of the Company with effect from 26 November 2021. During the year 2022-23, the Company launched some complex tests using Next Generation Sequencing (NGS) Technology for Pre-natal screening, Breast Cancer, Bone Marrow Transplant and Allergy Component Testing powered by Artificial Intelligence. In FY 23, it added 14 labs and approximately 548 centers during the year, built a new management team to run the business, integrated the technology offering with Metropolis and executed some cost synergies; further added 83 new tests. During year 2022-23, the subsidiary companies, M/s. Bokil Golwilkar Metropolis Healthcare Private Limited, M/s. Desai Metropolis Health Services Private Limited, M/s. Dr. Patel Metropolis Healthcare Private Limited, M/s. Lab One Metropolis Healthcare Services Private Limited, M/s. Micron Metropolis Healthcare Private Limited, M/s. R. V. Metropolis Diagnostic & Health Care Center Private Limited, M/s. Raj Metropolis Healthcare Private Limited and M/s. Sudharma Metropolis Health Services Private got merged with the Company through the Scheme of Amalgamation, which was made effective from July 11, 2022. The Company expanded its network, marking the presence to 600 towns across India. In 2023-24, it launched over 100 advanced tests, including Comprehensive testing for food and drug allergies using AI, Syndromic Multiplex PCR Testing for infectious diseases, and Next Generation Sequencing-based tests for various conditions, including predictive biomarkers for cancer immunotherapy. Further, the Next Best Action (NBA) initiative-a comprehensive program designed to empower patients and prevent severe complications from chronic diseases launched in FY24. The Company expanded the lab footprint by nearly 90 labs and scaled the network of owned Patient Service Centers from ~251 (FY22) to over 530 in FY 2025. It opened 11 new laboratories and acquired Core Diagnostics Private Limited, a leading Delhi-NCR specializing in oncology and genomics. It expanded the business by acquiring Scientific Pathology in Agra, Uttar Pradesh and Dr. Ahuja's Pathology & Imaging Centre, Dehradun in Uttarakhand in FY 2025. The Company expanded its footprint by adding approximately 490 service centres, taking its network to 5,026 service touchpoints across more than 750 towns, thereby strengthening high-growth markets and improving access to quality diagnostics in 2026.

    Trade now

    Fundamentals

    Financial strength and ownership structure

    Valuation & Ratios

    Market Capitalisation

    ₹8,992.84

    Price to Book (PB)

    5.99

    Price to Earnings (PE)

    47.30

    Return on Equity (ROE)

    13.44%

    Earnings Per Share (EPS)

    9.22

    Dividend Yield

    1.15%

    Financial Performance

    291.12
    331
    313.36
    349.79
    322.77
    345.29
    386.06
    429.19
    405.91
    424.68
    450.22
    496.82
    Dec
    '23
    Mar
    '24
    Jun
    '24
    Sep
    '24
    Dec
    '24
    Mar
    '25
    Jun
    '25
    Sep
    '25
    Dec
    '25
    Mar
    '26
    Jun
    '26
    Sep
    '26

    Shareholding Pattern

    48.88%
    48.87%
    48.86%
    47.82%
    Dec
    '25
    Mar
    '26
    Jun
    '26
    Sep
    '26